Three months' treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate
Three months' treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostate
复制标题
DOI：
10.1038/sj.pcan.4500849
复制
发表时间：
2006-06-01
影响因子：
4.8
通讯作者：
Roehrborn, C. G.
中科院分区：
文献类型：
--
作者：
Roehrborn, C. G.
α 1肾上腺素能受体阻滞剂治疗可改善良性前列腺增生继发的下尿路症状（LUTS）。本研究旨在检验以下假设：前列腺组织中细胞凋亡的诱导可能是观察到的临床获益的潜在机制。这项安慰剂对照、双盲、随机化试验入组了536例接受阿夫唑嗪（10或15 mg）每日一次或安慰剂治疗3个月的LUTS男性。在基线和3个月时通过标准化经直肠超声测量总前列腺和移行区体积。安慰剂组患者的前列腺总体积较基线增加0.4 ml，但阿夫唑嗪联合治疗组患者的前列腺总体积较基线减少-0.25 ml。安慰剂组和阿夫唑嗪组之间的百分比变化无统计学显著性差异。两个治疗组的移行区体积较基线的变化相似;安慰剂组和阿夫唑嗪组之间的百分比变化无统计学显著差异。体积变化与基线时的前列腺体积无关。总体而言，在3个月治疗期间，总前列腺体积和移行区体积均未系统性增加或减少。如果阿夫唑嗪诱导前列腺组织的细胞凋亡，在治疗3个月后前列腺体积的可测量变化并不明显。1年和2年的进一步分析将确定长期治疗的效果。
Treatment with alpha(1)-adrenergic receptor blockers improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia. This study was conducted to test the hypothesis that induction of apoptosis in prostate tissue could be a mechanism underlying the observed clinical benefit. This placebo-controlled, double-blind, randomized trial enrolled 536 men with LUTS who were treated with alfuzosin ( 10 or 15 mg) once daily or placebo for 3 months. Total prostate and transition zone volume was measured by standardized transrectal ultrasound measurements at baseline and 3 months. Total prostate volume increased by 0.4 ml from baseline in placebo patients but decreased by - 0.25 ml in the combined alfuzosin groups. Percentage change was not statistically significantly different between the placebo and alfuzosin groups. Changes in transition zone volumes from baseline were similar in both treatment arms; percentage change was not statistically significantly different between the placebo and alfuzosin groups. Volume changes did not correlate with prostate volumes at baseline. Overall, neither total prostate nor transition zone volume increased or decreased systematically within the 3-month treatment period. If alfuzosin-induced apoptosis in prostate tissue, it was not evident by a measurable change in prostate volume after 3 months' treatment. Further analysis at 1 and 2 years will determine the effect of longer-term treatment.